Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Kimberly Blackwell net worth and biography

Kimberly Blackwell Biography and Net Worth

Director of Zentalis Pharmaceuticals

Dr. Kimberly Blackwell currently serves as Chief Medical Officer and Senior Vice President, Oncology Clinical Development, at Tempus Labs. In this role, she oversees precision medicine initiatives to improve cancer care and guide therapeutic drug development and discovery. Prior to joining Tempus, she was VP of Early Phase Oncology and Immunology-oncology at Eli Lilly and Company, where she worked on early stage cancer therapeutics. During her time at Lilly, she was named as one of “Twenty extraordinary women in biopharma R&D who worked their way to the top” by Endpoints News. For 18 years, Dr. Blackwell was a faculty member at the Duke University Cancer Institute. While at Duke, she served as the principal or co-principal investigator for over 50 cancer clinical trials, co-founded the radiotherapeutics company-Cereius, and co-directed the Woman’s Cancer Program and Precision Medicine Initiative. As one of the nation’s leading breast cancer researchers, she played a role in developing therapies that represent revolutionary non-chemotherapy-based approaches for treating cancer. This work led to Dr. Blackwell’s inclusion in TIME Magazine’s 100 Most Influential People in the World for 2013, recognizing her accomplishments contributing to the development of lapatinib and T-DM1 for the treatment of HER2+ breast cancer. She holds a BA degree in Bioethics from Duke University and a MD degree from Mayo Clinic Medical School.

What is Kimberly Blackwell's net worth?: The estimated net worth of Kimberly Blackwell is at least $884,156.00 as of November 13th, 2023. Dr. Blackwell owns 254,800 shares of Zentalis Pharmaceuticals stock worth more than $884,156 as of November 17th. This net worth estimate does not reflect any other investments that Dr. Blackwell may own. Additionally, Dr. Blackwell receives an annual salary of $1,170,000.00 as Director at Zentalis Pharmaceuticals. Learn More about Kimberly Blackwell's net worth.
How old is Kimberly Blackwell?: Dr. Blackwell is currently 55 years old. There are 6 older executives and no younger executives at Zentalis Pharmaceuticals. Learn More on Kimberly Blackwell's age.
What is Kimberly Blackwell's salary?: As the Director of Zentalis Pharmaceuticals, Inc., Dr. Blackwell earns $1,170,000.00 per year. Learn More on Kimberly Blackwell's salary.
How do I contact Kimberly Blackwell?: The corporate mailing address for Dr. Blackwell and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected]. Learn More on Kimberly Blackwell's contact information.
Has Kimberly Blackwell been buying or selling shares of Zentalis Pharmaceuticals?: Kimberly Blackwell has not been actively trading shares of Zentalis Pharmaceuticals during the last ninety days. Most recently, on Monday, November 13th, Kimberly Blackwell bought 5,000 shares of Zentalis Pharmaceuticals stock. The stock was acquired at an average cost of $10.29 per share, with a total value of $51,450.00. Following the completion of the transaction, the chief executive officer now directly owns 254,800 shares of the company's stock, valued at $2,621,892. Learn More on Kimberly Blackwell's trading history.
Who are Zentalis Pharmaceuticals' active insiders?: Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Zentalis Pharmaceuticals?: In the last twelve months, insiders at the sold shares 5 times. They sold a total of 18,302 shares worth more than $205,276.56. The most recent insider tranaction occured on October, 4th when insider Vincent Vultaggio sold 1,603 shares worth more than $5,097.54. Insiders at Zentalis Pharmaceuticals own 3.6% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.
Information on this page was last updated on 10/4/2024.

Kimberly Blackwell Insider Trading History at Zentalis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/13/2023	Buy	5,000	$10.29	$51,450.00	254,800
1/3/2022	Sell	1,000	$83.74	$83,740.00
12/1/2021	Sell	1,000	$81.84	$81,840.00
11/1/2021	Sell	1,000	$80.46	$80,460.00
10/25/2021	Sell	1,000	$77.59	$77,590.00

Kimberly Blackwell Buying and Selling Activity at Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Today's Range

Now: $3.47

$3.36

$4.00

50 Day Range

MA: $3.42

$2.70

$4.36

2 Week Range

Now: $3.47

$2.66

$18.07

Volume

1,832,087 shs

Average Volume

1,566,191 shs

Market Capitalization

$247.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74

This company will win the AI race

From Porter & Company | Ad

You must read this new presentation from Porter Stansberry.

Kimberly Blackwell Biography and Net Worth

What is Kimberly Blackwell's net worth?

How old is Kimberly Blackwell?

What is Kimberly Blackwell's salary?

How do I contact Kimberly Blackwell?

Has Kimberly Blackwell been buying or selling shares of Zentalis Pharmaceuticals?

Who are Zentalis Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Zentalis Pharmaceuticals?